Literature DB >> 25834312

Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Juan-Ramón Larrubia1, Elia Moreno-Cubero1, Joaquín Miquel1, Eduardo Sanz-de-Villalobos1.   

Abstract

Hepatitis C virus (HCV)-specific cytotoxic T cell (CTL) response plays a major role in viral control during spontaneous infection resolution. These cells develop an exhausted and pro-apoptotic status during chronic onset, being unable to get rid of HCV. The role of this response in contributing to sustained viral response (SVR) after anti-HCV is controversial. Recent studies show that after successful interferon-based anti-HCV treatment, HCV traces are still detectable and this correlates with a peak of HCV-specific CTL response activation, probably responsible for maintaining SVR by subsequent complete HCV clearing. Moreover, SVR patients' serum is still able to induce HCV infection in naïve chimpanzees, suggesting that the infection could be under the control of the immune system after a successful treatment, being transmissible in absence of this adaptive response. At least theoretically, treatment-induced viral load decrease could allow an effective HCV-specific CTL response reestablishment. This effect has been recently described with anti-HCV interferon-free regimes, based on direct-acting antivirals. Nevertheless, this is to some extent controversial with interferon-based therapies, due to the detrimental immunoregulatory α-interferon effect on T cells. Moreover, HCV-specific CTL response features during anti-HCV treatment could be a predictive factor of SVR that could have clinical implications in patient management. In this review, the recent knowledge about the role of HCV-specific CTL response in the development of SVR after anti-HCV treatment is discussed.

Entities:  

Keywords:  Apoptosis; Chronic hepatitis; Direct-acting antivirals; Exhaustion; Hepatitis C virus; Hepatitis C virus-specific cytotoxic T cell response; Interferon-alpha; Ribavirin; Treatment

Mesh:

Substances:

Year:  2015        PMID: 25834312      PMCID: PMC4375569          DOI: 10.3748/wjg.v21.i12.3480

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  93 in total

1.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

2.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

3.  HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution.

Authors:  Juan-Ramón Larrubia; Megha-Uttam Lokhande; Elia Moreno-Cubero; Silvia García-Garzón; Joaquín Miquel; Trinidad Parra-Cid; Alejandro González-Praetorious; Cristian Perna; Alicia Lázaro; Eduardo Sanz-de-Villalobos
Journal:  Cell Immunol       Date:  2013-11-13       Impact factor: 4.868

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

5.  Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Rami Moucari; Nathalie Boyer; Marie-Pierre Ripault; Dominique Cazals-Hatem; Nathalie Giuily; Corinne Castelnau; Ana Carolina Cardoso; Tarik Asselah; Cyrille Féray; Marie Hélène Nicolas-Chanoine; Pierre Bedossa; Patrick Marcellin
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

6.  Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia.

Authors:  Flavien Bernardin; Leslie Tobler; Irina Walsh; Joan Dunn Williams; Mike Busch; Eric Delwart
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

7.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

8.  Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.

Authors:  Silke Paust; Harvinder S Gill; Bao-Zhong Wang; Michael P Flynn; E Ashley Moseman; Balimkiz Senman; Marian Szczepanik; Amalio Telenti; Philip W Askenase; Richard W Compans; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2010-10-24       Impact factor: 25.606

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection.

Authors:  Kathrin Gibbert; Jara J Joedicke; Andreas Meryk; Mirko Trilling; Sandra Francois; Janine Duppach; Anke Kraft; Karl S Lang; Ulf Dittmer
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

View more
  11 in total

1.  Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.

Authors:  Noy Ashkenazy; Carol L Karp; Gaofeng Wang; Carolina Mercado Acosta; Anat Galor
Journal:  Cornea       Date:  2017-04       Impact factor: 2.651

Review 2.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

Review 3.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Authors:  Elia Moreno-Cubero; Juan-Ramón Larrubia
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 4.  Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression.

Authors:  Pier-Angelo Tovo; Carmelina Calitri; Carlo Scolfaro; Clara Gabiano; Silvia Garazzino
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.

Authors:  C Carlton-Smith; J A Holmes; S Naggie; A Lidofsky; G M Lauer; A Y Kim; R T Chung
Journal:  J Viral Hepat       Date:  2017-12-27       Impact factor: 3.728

Review 6.  Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.

Authors:  Miguel Jiménez-Pérez; Rocío González-Grande; Pilar España Contreras; Isabel Pinazo Martínez; Jesús de la Cruz Lombardo; Raúl Olmedo Martín
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

7.  NKG2A is a NK cell exhaustion checkpoint for HCV persistence.

Authors:  Chao Zhang; Xiao-Mei Wang; Shu-Ran Li; Trix Twelkmeyer; Wei-Hong Wang; Sheng-Yuan Zhang; Shu-Feng Wang; Ji-Zheng Chen; Xia Jin; Yu-Zhang Wu; Xin-Wen Chen; Sheng-Dian Wang; Jun-Qi Niu; Hai-Rong Chen; Hong Tang
Journal:  Nat Commun       Date:  2019-04-03       Impact factor: 14.919

8.  Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases.

Authors:  Ichiro Tamaki; Toshimi Kaido; Shintaro Yagi; Yoshihide Ueda; Etsuro Hatano; Hideaki Okajima; Shinji Uemoto
Journal:  Surg Case Rep       Date:  2015-12-24

9.  Investigation of the Immunomodulatory effect of Berberis vulgaris on core-pulsed dendritic cell vaccine.

Authors:  Doaa A Ghareeb; Eiman H Elwakeel; Rowaida Khalil; Mina S Aziz; Maha A El Demellawy
Journal:  BMC Complement Altern Med       Date:  2016-08-30       Impact factor: 3.659

10.  Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients.

Authors:  Grenda Leite Pereira; Andréa Monteiro Tarragô; Walter Luiz Lima Neves; Pedro Vieira da Silva Neto; Priscila Sarmento de Souza; Juliana Dos Santos Affonso; Keyla Santos de Sousa; Jéssica Albuquerque da Silva; Allyson Guimarães Costa; Flamir da Silva Victoria; Marilu Barbieri Victoria; Adriana Malheiro
Journal:  Mediators Inflamm       Date:  2019-11-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.